Literature DB >> 17400507

Identification of potential protein interactors of Lrrk2.

Justus C Dächsel1, Julie P Taylor, Su San Mok, Owen A Ross, Kelly M Hinkle, Rachel M Bailey, Jacob H Hines, Jennifer Szutu, Benjamin Madden, Leonard Petrucelli, Matthew J Farrer.   

Abstract

Pathogenic substitutions in the Lrrk2 protein have been shown to be an important cause of both familial and sporadic parkinsonism. The molecular pathway involved in Lrrk2 dopaminergic neuron degeneration remains elusive. Employing a combination of Lrrk2-mediated protein precipitation and tandem mass spectrometry, we identified 14 potential Lrrk2 binding partners. The majority of these interactions may be subgrouped into three functional cellular pathways: (i) chaperone-mediated response, (ii) proteins associated with the cytoskeleton and trafficking and (iii) phosphorylation and kinase activity. Future investigation of these candidates is now warranted and may help resolve the pathomechanism behind Lrrk2 neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400507      PMCID: PMC2970619          DOI: 10.1016/j.parkreldis.2007.01.008

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  13 in total

1.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

2.  The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence.

Authors:  E K Tan; Y Zhao; L Skipper; M G Tan; A Di Fonzo; L Sun; S Fook-Chong; S Tang; E Chua; Y Yuen; L Tan; R Pavanni; M C Wong; P Kolatkar; C S Lu; V Bonifati; J J Liu
Journal:  Hum Genet       Date:  2006-09-30       Impact factor: 4.132

3.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.

Authors:  Christian Johannes Gloeckner; Norbert Kinkl; Annette Schumacher; Ralf J Braun; Eric O'Neill; Thomas Meitinger; Walter Kolch; Holger Prokisch; Marius Ueffing
Journal:  Hum Mol Genet       Date:  2005-12-01       Impact factor: 6.150

4.  Biochemical and pathological characterization of Lrrk2.

Authors:  Benoit I Giasson; Jason P Covy; Nancy M Bonini; Howard I Hurtig; Matthew J Farrer; John Q Trojanowski; Vivianna M Van Deerlin
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

5.  Lrrk2 pathogenic substitutions in Parkinson's disease.

Authors:  Ignacio F Mata; Jennifer M Kachergus; Julie P Taylor; Sarah Lincoln; Jan Aasly; Timothy Lynch; Mary M Hulihan; Stephanie A Cobb; Ruey-Meei Wu; Chin-Song Lu; Carlos Lahoz; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

6.  The Parkinson disease gene LRRK2: evolutionary and structural insights.

Authors:  Ignacio Marín
Journal:  Mol Biol Evol       Date:  2006-09-11       Impact factor: 16.240

7.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

Authors:  Andrew B West; Darren J Moore; Saskia Biskup; Artem Bugayenko; Wanli W Smith; Christopher A Ross; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

8.  Localization of LRRK2 to membranous and vesicular structures in mammalian brain.

Authors:  Saskia Biskup; Darren J Moore; Fulvio Celsi; Shinji Higashi; Andrew B West; Shaida A Andrabi; Kaisa Kurkinen; Seong-Woon Yu; Joseph M Savitt; Henry J Waldvogel; Richard L M Faull; Piers C Emson; Reidun Torp; Ole P Ottersen; Ted M Dawson; Valina L Dawson
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

9.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

Authors:  Elisa Greggio; Shushant Jain; Ann Kingsbury; Rina Bandopadhyay; Patrick Lewis; Alice Kaganovich; Marcel P van der Brug; Alexandra Beilina; Jeff Blackinton; Kelly Jean Thomas; Rili Ahmad; David W Miller; Sashi Kesavapany; Andrew Singleton; Andrew Lees; Robert J Harvey; Kirsten Harvey; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2006-06-05       Impact factor: 5.996

10.  LRRK2 expression in normal and pathologic human brain and in human cell lines.

Authors:  Judith Miklossy; Tetsuaki Arai; Jian-Ping Guo; Andis Klegeris; Sheng Yu; Edith G McGeer; Patrick L McGeer
Journal:  J Neuropathol Exp Neurol       Date:  2006-10       Impact factor: 3.685

View more
  37 in total

1.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

Review 2.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

3.  The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules.

Authors:  Payal N Gandhi; Xinglong Wang; Xiongwei Zhu; Shu G Chen; Amy L Wilson-Delfosse
Journal:  J Neurosci Res       Date:  2008-06       Impact factor: 4.164

4.  The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2.

Authors:  Lizhen Wang; Chengsong Xie; Elisa Greggio; Loukia Parisiadou; Hoon Shim; Lixin Sun; Jayanth Chandran; Xian Lin; Chen Lai; Wan-Jou Yang; Darren J Moore; Ted M Dawson; Valina L Dawson; Gabriela Chiosis; Mark R Cookson; Huaibin Cai
Journal:  J Neurosci       Date:  2008-03-26       Impact factor: 6.167

5.  The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.

Authors:  Moh'd A Salameh; Jessica L Robinson; Duraiswamy Navaneetham; Dipali Sinha; Benjamin J Madden; Peter N Walsh; Evette S Radisky
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

Review 6.  LRRK2 Pathways Leading to Neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

7.  Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.

Authors:  Xiaodong Ding; Sandeep K Barodia; Lisha Ma; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2016-11-24       Impact factor: 5.996

8.  The 19-amino acid insertion in the tumor-associated splice isoform Rac1b confers specific binding to p120 catenin.

Authors:  Lidiya Orlichenko; Rory Geyer; Masahiro Yanagisawa; Davitte Khauv; Evette S Radisky; Panos Z Anastasiadis; Derek C Radisky
Journal:  J Biol Chem       Date:  2010-04-15       Impact factor: 5.157

Review 9.  Purine-scaffold Hsp90 inhibitors.

Authors:  Tony Taldone; Gabriela Chiosis
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

10.  The WD40 domain is required for LRRK2 neurotoxicity.

Authors:  Nathan D Jorgensen; Yong Peng; Cherry C-Y Ho; Hardy J Rideout; Donald Petrey; Peng Liu; William T Dauer
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.